ACHVのニュース
Achieve Life Sciences: Initiating Buy, Potential Multi-Billion-Dollar Smoking Cessation Drug 2022/04/04 17:38:57 Seeking Alpha
Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q4 2021 Results - Earnings Call Transcript 2022/03/10 23:04:08 Seeking Alpha
Achieve Life Sciences GAAP EPS of -$0.76 misses by $0.07 2022/03/10 14:29:13 Seeking Alpha
Achieve Life Sciences press release (ACHV): Q4 GAAP EPS of -$0.76 misses by $0.07.As of December 31, 2021, the company’s cash, cash equivalents, and restricted cash was $43.1 million.
Achieve Life Sciences Q4 2021 Earnings Preview (NASDAQ:ACHV) 2022/03/09 22:35:33 Seeking Alpha
Achieve Life Sciences (NASDAQ:ACHV) is scheduled to announce Q4 earnings results on Thursday, March 10th, after market close.The consensus EPS Estimate is -$0.70 (+36.9% Y/Y) and…
Achieve Life commences Phase 3 trial of cytisinicline for smoking cessation 2022/01/25 13:26:01 Seeking Alpha
Achieve Life Sciences (ACHV) has initiated screening of ORCA-3, the confirmatory Phase 3 trial required for registrational approval of cytisinicline in U.S. ORCA-3 will evaluate
Achieve Life Sciences: Initiating Buy, Potential Multi-Billion-Dollar Smoking Cessation Drug 2022/04/04 17:38:57 Seeking Alpha
Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q4 2021 Results - Earnings Call Transcript 2022/03/10 23:04:08 Seeking Alpha
Achieve Life Sciences GAAP EPS of -$0.76 misses by $0.07 2022/03/10 14:29:13 Seeking Alpha
Achieve Life Sciences press release (ACHV): Q4 GAAP EPS of -$0.76 misses by $0.07.As of December 31, 2021, the company’s cash, cash equivalents, and restricted cash was $43.1 million.
Achieve Life Sciences Q4 2021 Earnings Preview (NASDAQ:ACHV) 2022/03/09 22:35:33 Seeking Alpha
Achieve Life Sciences (NASDAQ:ACHV) is scheduled to announce Q4 earnings results on Thursday, March 10th, after market close.The consensus EPS Estimate is -$0.70 (+36.9% Y/Y) and…
Achieve Life commences Phase 3 trial of cytisinicline for smoking cessation 2022/01/25 13:26:01 Seeking Alpha
Achieve Life Sciences (ACHV) has initiated screening of ORCA-3, the confirmatory Phase 3 trial required for registrational approval of cytisinicline in U.S. ORCA-3 will evaluate
Achieve Life Sciences: Initiating Buy, Potential Multi-Billion-Dollar Smoking Cessation Drug 2022/04/04 17:38:57 Seeking Alpha
Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q4 2021 Results - Earnings Call Transcript 2022/03/10 23:04:08 Seeking Alpha
Achieve Life Sciences GAAP EPS of -$0.76 misses by $0.07 2022/03/10 14:29:13 Seeking Alpha
Achieve Life Sciences press release (ACHV): Q4 GAAP EPS of -$0.76 misses by $0.07.As of December 31, 2021, the company’s cash, cash equivalents, and restricted cash was $43.1 million.